JP2013508450A - Ｆｔｓおよびそのアナログによる甲状腺がん治療のための組成物 - Google Patents

Ｆｔｓおよびそのアナログによる甲状腺がん治療のための組成物 Download PDF

Info

Publication number
JP2013508450A
JP2013508450A JP2012536011A JP2012536011A JP2013508450A JP 2013508450 A JP2013508450 A JP 2013508450A JP 2012536011 A JP2012536011 A JP 2012536011A JP 2012536011 A JP2012536011 A JP 2012536011A JP 2013508450 A JP2013508450 A JP 2013508450A
Authority
JP
Japan
Prior art keywords
fts
ras
thyroid cancer
cells
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012536011A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013508450A5 (cg-RX-API-DMAC10.html
Inventor
クルーグ，ヨエル
レヴィ，ラン
Original Assignee
ラモット・アット・テル−アヴィヴ・ユニヴァーシティ・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラモット・アット・テル−アヴィヴ・ユニヴァーシティ・リミテッド filed Critical ラモット・アット・テル−アヴィヴ・ユニヴァーシティ・リミテッド
Publication of JP2013508450A publication Critical patent/JP2013508450A/ja
Publication of JP2013508450A5 publication Critical patent/JP2013508450A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2012536011A 2009-10-26 2010-10-26 Ｆｔｓおよびそのアナログによる甲状腺がん治療のための組成物 Pending JP2013508450A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25487909P 2009-10-26 2009-10-26
US61/254,879 2009-10-26
PCT/IL2010/000883 WO2011051938A1 (en) 2009-10-26 2010-10-26 Composition for treatment of thyroid cancer with fts and analogs thereof

Publications (2)

Publication Number Publication Date
JP2013508450A true JP2013508450A (ja) 2013-03-07
JP2013508450A5 JP2013508450A5 (cg-RX-API-DMAC10.html) 2013-11-14

Family

ID=43446628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012536011A Pending JP2013508450A (ja) 2009-10-26 2010-10-26 Ｆｔｓおよびそのアナログによる甲状腺がん治療のための組成物

Country Status (2)

Country Link
JP (1) JP2013508450A (cg-RX-API-DMAC10.html)
WO (1) WO2011051938A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015182625A1 (ja) * 2014-05-26 2015-12-03 国立大学法人京都大学 Ｒａｓ活性阻害薬及びその用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09508618A (ja) * 1993-11-12 1997-09-02 ラモツト・ユニバーシテイ・オーソリテイ・フオー・アプライド・リサーチ・アンド・インダストリアル・デベロツプメント・リミテツド ファルネシル誘導体およびそれらを含む医薬組成物
WO2007116396A1 (en) * 2006-04-11 2007-10-18 Ramot At Tel Aviv University Ltd. Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09508618A (ja) * 1993-11-12 1997-09-02 ラモツト・ユニバーシテイ・オーソリテイ・フオー・アプライド・リサーチ・アンド・インダストリアル・デベロツプメント・リミテツド ファルネシル誘導体およびそれらを含む医薬組成物
WO2007116396A1 (en) * 2006-04-11 2007-10-18 Ramot At Tel Aviv University Ltd. Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6014037385; Ｃａｎｃｅｒ　Ｃｈｅｍｏｔｈｅｒ．　Ｐｈａｒｍａｃｏｌ． Ｖｏｌ．６５, 200905, ｐｐ．２３５-２４１ *
JPN6014037386; Ｊ．　Ｃｌｉｎ．　Ｏｎｃｏｌ． Ｖｏｌ．２６　Ｎｏ．３９, 2008, ｐｐ．４７０８-４７１３ *
JPN6015018058; Ｍｏｌ．　Ｍｅｄ． Ｖｏｌ．６　Ｎｏ．８, 2000, ｐｐ．６９３-７０４ *
JPN6015018060; Ｂｉｏｃｈｉｍ．　Ｂｉｏｐｈｙｓ．　Ａｃｔａ Ｖｏｌ．１４５２, 1999, ｐｐ．２２８-２４２ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015182625A1 (ja) * 2014-05-26 2015-12-03 国立大学法人京都大学 Ｒａｓ活性阻害薬及びその用途

Also Published As

Publication number Publication date
WO2011051938A1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
Lam et al. Renal disease in tuberous sclerosis complex: pathogenesis and therapy
ES2685947T3 (es) Agentes antienvejecimiento
US8110550B2 (en) HDAC inhibitors and hormone targeted drugs for the treatment of cancer
El Touny et al. Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells
Bai et al. Curcumin inhibits cardiac hypertrophy and improves cardiovascular function via enhanced Na+/Ca2+ exchanger expression after transverse abdominal aortic constriction in rats
Zou et al. C/EBPβ knockdown protects cardiomyocytes from hypertrophy via inhibition of p65-NFκB
US10722493B2 (en) Methods for treating fibroproliferative disorders in a mammal
US11278549B2 (en) Method of treating obesity
Wang et al. Transient receptor potential vanilloid type 1 protects against pressure overload–induced cardiac hypertrophy by promoting mitochondria-associated endoplasmic reticulum membranes
Fernando et al. Phloridzin docosahexaenoate, a novel fatty acid ester of a plant polyphenol, inhibits mammary carcinoma cell metastasis
EP2945646A1 (en) Estrogen receptor inhibitors
CN115813892B (zh) 原儿茶醛与达卡巴嗪的药物联合及其在治疗恶性黑色素瘤中的用途
WO2020139999A1 (en) Pancreatic cancer treatment
Huang et al. Harmine attenuates renal fibrosis via Twist1 suppression: A novel anti-fibrotic strategy for chronic kidney disease with efficacy/safety profiling
WO2011051938A1 (en) Composition for treatment of thyroid cancer with fts and analogs thereof
CN110548020B (zh) 亚精胺在制备治疗主动脉瘤药物方面的应用
US20110046223A1 (en) Treatment of neurofibromatosis
Liu et al. Autophagy Protease ATG4D Facilitates Proliferation and Malignancy of Osteosarcoma Cells
WO2011103563A1 (en) Methods and compositions for inhibiting and preventing the growth of malignant mast cells
Tang et al. PRC1 mediates downstream PI3K-AKT activation through regulating PTEN ubiquitination degradation in TAC-induced cardiac remodeling
KR102459443B1 (ko) Ac_774를 포함하는 흑색종 예방 또는 치료용 조성물
JP2013508458A (ja) Ｆｔｓとｈｄａｃ阻害剤との組合せを用いたがん治療
Liu et al. A copper-based ascorbic acid-activatable gel for postoperative glioblastoma therapy
WO2022084947A1 (en) Mitochondrial atp inhibitors targeting the gamma subunit prevent metastasis
EP3846789A1 (en) A novel anti-cancer combination and a method of therapy using the combination

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141202

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151013

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160129